Fluticasone furoate/vilanterol

Drug Profile

Fluticasone furoate/vilanterol

Alternative Names: '444/'698; 444/698; Breo Ellipta; FF/GW642444; FF/VI; Fluticasone furoate/GW642444; Fluticasone furoate/vilanterol trifenatate; GSK-2285997; GW642444/GW685698; GW642444M/GW685698X; GW685698/GW642444; GW685698X/GW642444M; Relovair; Relvar Ellipta; Revinty Ellipta

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline; Innoviva
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorobenzenes; Ethers; Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 17 Nov 2017 GlaxoSmithKline plans a phase II trial for Asthma (In children, In adolescents) in Germany (EudraCT2016-004086-87)
  • 20 Oct 2017 GlaxoSmithKline initiates enrolment in a phase III trial for Asthma (In children, In adolescents) (Inhalation, Powder) (NCT03248128)
  • 11 Sep 2017 Efficacy data from a phase III trial (Salford Lung Study) in Chronic obstructive pulmonary disease released by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top